News & Updates

Show Multimedia Only
Ritlecitinib, brepocitinib superior to placebo for inducing remission in UC

Ritlecitinib, brepocitinib superior to placebo for inducing remission in UC

13 Jan 2023

Ritlecitinib and brepocitinib as induction therapies for ulcerative colitis (UC) appear to be more effective than placebo while having an acceptable short-term safety profile, according to the results of a phase IIb study.

Ritlecitinib, brepocitinib superior to placebo for inducing remission in UC

13 Jan 2023
Regular coffee intake may lower T2D risk in women with gestational diabetes

Regular coffee intake may lower T2D risk in women with gestational diabetes

13 Jan 2023 byStephen Padilla

Women with a history of gestational diabetes mellitus (GDM) may benefit from habitual consumption of caffeinated coffee to prevent progression to type 2 diabetes (T2D) and have a more favourable metabolic profile, suggests a study.

Regular coffee intake may lower T2D risk in women with gestational diabetes

13 Jan 2023
Regdanvimab for COVID-19 effective against Delta variant

Regdanvimab for COVID-19 effective against Delta variant

13 Jan 2023

The neutralizing antibody regdanvimab appears to be useful in the treatment of mild-to-moderate COVID-19, with a recent study showing that the drug may prevent disease worsening in patients, including those infected with the Delta variant.

Regdanvimab for COVID-19 effective against Delta variant

13 Jan 2023
IOP-induced ONH strains negatively tied to retinal sensitivity in glaucoma patients

IOP-induced ONH strains negatively tied to retinal sensitivity in glaucoma patients

12 Jan 2023